Clinical trials: Graft-Versus-Host Disease
Graft vs Host Disease, Mesenchymal Stem Cell Transplantation
Use of Bone Marrow Stem Cells (MesenCell) for the Treatment of Patients With Chronic Graft-versus-host Disease
The purpose of this Phase I clinical trial is to evaluate the safety and potential treatment response of bone marrow-derived mesenchymal stem cells (MesenCell) in adult patients with moderate or severe chronic graft-versus-host…
- Trial name
- NCT07826676
- Testing
- Mesenchymal Stem Cell Infusion
- Where
- 4 sites in Brazil
- Volunteers
- 20 people
- Sponsor
- Pontifícia Universidade Católica do Paraná
Prostatitis, Chronic Prostatitis With Chronic Pelvic Pain Syndrome
Laparoscopic Prostatectomy for Chronic Prostatitis
Prostatitis is an inflammation of the prostate, an pelvic organ of men. Prostatitis can cause great discomfort which varies but can include pelvic pain, pelvic pressure, a vague sense of discomfort, a feeling of malaise and…
- Trial name
- NCT00775515
- Testing
- laparoscopic prostatectomy
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- The Krongrad Institute
Chronic Graft Versus Host Disease
Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease
This is an open-label, Phase 2 study designed to evaluate the safety and efficacy of belumosudil and rituximab as primary treatment of cGVHD.
- Trial name
- NCT06046248
- Testing
- Belumosudil, Rituximab
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Northside Hospital, Inc.
Cholecystitis, Chronic
Outcomes of Three Ports Versus Four Ports Laparoscopic Cholecystectomy, Sohag General Surgery Department Experience
To compare the outcomes of three ports and four ports Laparoscopic Cholecystectomy
- Trial name
- NCT06264115
- Testing
- Laparoscopic Cholecystectomy
- Where
- Egypt
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Sohag University
Graft Versus Host Disease, Leukemia
Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant
RATIONALE: A donor peripheral stem cell transplant helps stop the growth of cancer cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood…
- Conditions
- Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00725062
- Testing
- CD4+CD25+ regulatory T cells, allogeneic hematopoietic stem cell transplantation
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Hematologic Malignancies, Bone Marrow Transplant Rejection
Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignancies
This study will evaluate the safety and effectiveness of stem cell transplantation in which the donor's T cells (a type of lymphocyte, or white blood cell) are removed and then added back.
- Trial name
- NCT00079391
- Testing
- allogeneic hematopoietic stem cell transplantation
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Acute Graft-versus-host Disease
MSCs Combined With CD25 Monoclonal Antibody and Calcineurin Inhibitors for Treatment of Steroid-resistant aGVHD
The purpose of this study is to compare the efficacy of CD25 monoclonal antibody and calcineurin inhibitors with or without mesenchymal stem cells (MSCs) in treating patients with steroid-resistant acute graft-versus-host disease…
- Trial name
- NCT02241018
- Testing
- CD25 monoclonal antibody, calcineurin inhibitors, MSCs
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Acute Graft-versus-Host Disease
A Phase Ib Clinical Study of AC-003 Capsules in Subjects With aGVHD.
The study was an open-label, single-arm, dose-escalation, Phase Ib, multi-center study to investigate safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of AC-003 in patients with grade II-IV SR-aGVHD.
- Trial name
- NCT07070674
- Testing
- AC-003
- Where
- China
- Volunteers
- 4 people
- Sponsor
- Accro Bioscience (Suzhou) Limited
Previously Treated PH + CML
Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors
The purpose of this study is to fulfill the post-authorization commitment made by Pfizer to the European Medicines Agency in providing additional safety and efficacy data in approximately 150 Philadelphia Chromosome Positive…
- Trial name
- NCT02228382
- Testing
- Bosutinib
- Where
- 48 sites in United States, Austria and 6 more
- Volunteers
- 163 people
- Sponsor
- Pfizer
Graft Vs Host Disease
Cyclophosphamide, Abatacept, and Tacrolimus for the Prevention of GvHD
This is a single arm, open label, phase II clinical trial. Adult patients with hematological malignancies undergoing allogeneic HSCT from first- or second-degree haploidentical donor are eligible for the study if they meet the…
- Trial name
- NCT05621759
- Testing
- Cyclophosphamide, Abatacept, Tacrolimus
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- NYU Langone Health
Transfusion Dependent Thalassemia
Evaluation of Recombinant Humanized Anti-CD25 Monoclonal Antibody for Preventing Graft-versus-host Disease After Haploidentical/matched Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients with Transfusion-dependent Thalassemia
Graft-versus-host disease (GVHD) is a major factor affecting the efficacy and quality of life of alternative donor transplantation in thalassemia major (TM), severely limiting the clinical application of alternative donor…
- Trial name
- NCT06657391
- Testing
- recombinant humanized anti-CD25 monoclonal antibody
- Where
- 5 sites in China
- Volunteers
- 396 people
- Sponsor
- Rongrong Liu
Hematologic Malignancies
Safety Study of MultiStem® in Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplasia
The purpose of this study is to determine if MultiStem® can safely be given to patients with acute leukemia, chronic myeloid leukemia, or myelodysplasia after they have received hematopoietic stem cell transplantation.
- Trial name
- NCT00677859
- Testing
- MultiStem®
- Where
- 6 sites in United States, Belgium
- Volunteers
- 36 people
- Sponsor
- Healios K.K.
Tourette's Disorder, Persistent (Chronic) Motor or Vocal Tic Disorder
Internet-based Behaviour Therapy for Tourette's Disorder and Chronic Tic Disorder
The purpose of this study is to evaluate the feasibility and acceptability of two different modalities of therapist-guided Internet-delivered behaviour therapy (IBT) for children and adolescents (7-17 years) with Tourette's…
- Trial name
- NCT02864589
- Testing
- Internet-delivered habit reversal training, Internet-delivered exposure and response prevention
- Where
- Sweden
- Volunteers
- 23 people
- Sponsor
- Karolinska Institutet
Acute Leukemia, Myelodysplastic Syndromes
Sirolimus+Ruxolitinib+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to CNI
Graft-versus-host disease (GVHD) is an important complication after transplantation, with an incidence of 40-60%, which can increase non-relapse mortality if poorly controlled.
- Conditions
- Acute Leukemia, Myelodysplastic Syndromes, Severe Aplastic Anemia (SAA)
- Trial name
- NCT07796620
- Testing
- Sirolimus, Ruxolitinib, MMF
- Volunteers
- 40 people
- Sponsor
- Peking University People's Hospital
GVHD
High-Dose Post-Transplant Cyclophosphamide and Bortezomib (CyBor) for the Prevention of Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
This is a single arm open label phase II clinical trial. Adult patients with hematological malignancies undergoing allogeneic HSCT from matched-related or unrelated donor are eligible for the study if they meet the standard…
- Trial name
- NCT03945591
- Testing
- Bortezomib, Cyclophosphamide
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- NYU Langone Health
Chronic Graft-versus-host Disease
Mesenchymal Stem Cells for Treatment of Refractory Chronic Graft-versus-host Disease
The purpose of this study is to evaluate the utility of treating patients experiencing refractory chronic graft-versus-host disease with ex-vivo-expanded BM-drived mesenchymal stem cells from third-party donors.
- Trial name
- NCT01765660
- Testing
- Mesenchymal stem cells, Non-mesenchymal stem cells
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Blood Stem Cell Transplant Failure, Graft Versus Host Disease
Pilot Study: Patients With Chronic Active Graft Versus Host Disease That Have Failed or Not Tolerated Standard Therapy.
By doing this study, researchers hope to understand the many changes that occur in the blood of people who have chronic GvHD. This may also help the researcher understand how ECP works and help guide therapy for patients who have…
- Trial name
- NCT01174277
- Testing
- Collection of blood sample
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- University of Kansas Medical Center
Low Back Pain
Measurement of Substance P in Saliva of Low Back Pain Patients
The purpose of this study is to compare the levels of Substance P in saliva, in patients with severe chronic low back pain and in subjects without it.
- Trial name
- NCT00735735
- Testing
- The taking of a saliva sample from each subject.
- Where
- Spain
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Kovacs Foundation
Hematologic Malignancy
Donor Dendritic Cells And Donor Lymphocytes in Patients With Relapsed Hematologic Malignancies After Allogeneic Transplant
The purpose of this study is to test the safety of adding donor dendritic cells to donor lymphocyte infusions, and to determine the type and severity of any side effects associated with this addition.
- Trial name
- NCT00476177
- Testing
- Infusion of donor dendritic cells, Infusion of donor lymphocytes
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Dana-Farber Cancer Institute
B-Cell Chronic Lymphocytic Leukemia (B-CLL)
Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia
This is a Phase II, open-label, prospective, multicenter study to evaluate the efficacy and safety of subcutaneously administered alemtuzumab (CAMPATH, MabCampath) as therapy for patients with relapsed or refractory B-CLL who…
- Trial name
- NCT00328198
- Testing
- Alemtuzumab
- Where
- 21 sites in United States, Belgium and 4 more
- Volunteers
- 86 people
- Sponsor
- Genzyme, a Sanofi Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.